Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Website: boltbio.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 200.0%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -2 375.0%. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -114.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 29.0% higher than minimum and 95.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -106.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: BOLT  postmarket  1.12  (+1.8%)
Share price, USD:  (0.0%)1.1
year average price 1.2086  


year start price 1.6200 2023-05-08

max close price 1.9500 2023-05-15

min close price 0.8530 2023-11-30

current price 1.1000 2024-05-06
Common stocks: 37 471 700

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  > 200.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 5.1x
Margin (EBITDA LTM / Revenue): -2 375.0%
Fundamental value created in LTM:
Market Cap ($m): 41
Net Debt ($m): -21
EV (Enterprise Value): 20
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-09-05GlobeNewsWire

Bolt Biotherapeutics to Participate in September Investor Conferences

2023-07-31GlobeNewsWire

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

2023-04-26GlobeNewsWire

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-21 2023-11-09 2023-08-07 2023-05-11 2023-03-29 2022-11-10 2022-08-10
acceptedDate 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 2M 3M 1M 2M 1M 2M 1M
costOfRevenue 497 000 462 000 1M 0 0 0 0
grossProfit 2M 2M 244 000 2M 1M 2M 1M
grossProfitRatio 0.762 0.817 0.170 1.000 1.000 1.000 1.000
researchAndDevelopmentExpenses 16M 15M 16M 15M 17M 19M 19M
generalAndAdministrativeExpenses 6M 6M 6M 6M 6M 5M 6M
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 6M 6M 6M 6M 5M 6M
otherExpenses 0 0 0 0 0 0 0
operatingExpenses 21M 21M 21M 20M 22M 24M 24M
costAndExpenses 22M 21M 21M 20M 22M 24M 24M
interestIncome 2M 2M 2M 1M 1M 587 000 395 000
interestExpense 0 0 0 -1M -1M 587 000 395 000
depreciationAndAmortization 497 000 462 000 458 000 467 000 462 000 439 000 408 000
ebitda -19M -18M -19M -18M -21M -22M -22M
ebitdaratio -9.224 -7.193 -13.520 -9.829 -14.911 -10.373 -15.693
operatingIncome -20M -18M -20M -18M -21M -22M -23M
operatingIncomeRatio -9.462 -7.193 -13.839 -10.085 -14.911 -10.580 -16.553
totalOtherIncomeExpensesNet 2M 2M 2M 1M 1M 587 000 395 000
incomeBeforeTax -18M -16M -18M -17M -20M -22M -23M
incomeBeforeTaxRatio -8.570 -6.431 -12.601 -9.299 -14.172 -10.303 -16.270
incomeTaxExpense 0 -462 000 0 -1M -1M -587 000 0
netIncome -18M -16M -18M -16M -19M -21M -23M
netIncomeRatio -8.570 -6.431 -12.601 -8.513 -13.433 -10.025 -16.270
eps -0.470 -0.430 -0.480 -0.410 -0.500 -0.570 -0.610
epsdiluted -0.470 -0.430 -0.480 -0.410 -0.500 -0.570 -0.610
weightedAverageShsOut 38M 38M 38M 38M 38M 37M 37M
weightedAverageShsOutDil 38M 38M 38M 38M 38M 37M 37M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-21 2023-11-09 2023-08-07 2023-05-11 2023-03-29 2022-11-10 2022-08-10
acceptedDate 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 11M 9M 13M 15M 9M 11M 23M
shortTermInvestments 91M 111M 112M 112M 160M 161M 154M
cashAndShortTermInvestments 102M 120M 126M 126M 169M 171M 176M
netReceivables 1M 3M 2M 0 0 0 0
inventory 0 -3M -2M 0 0 0 0
otherCurrentAssets 2M 6M 5M 5M 4M 4M 5M
totalCurrentAssets 106M 125M 131M 132M 173M 175M 181M
propertyPlantEquipmentNet 24M 25M 26M 27M 29M 30M 29M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 28M 22M 31M 45M 24M 38M 47M
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 2M 3M 3M 3M 3M 3M 3M
totalNonCurrentAssets 54M 50M 60M 75M 55M 71M 79M
otherAssets 1.000 0 0 0 0 0 0
totalAssets 160M 175M 191M 206M 228M 246M 260M
accountPayables 3M 4M 3M 2M 4M 4M 3M
shortTermDebt 3M 3M 3M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 2M 2M 2M 2M 2M 3M 4M
otherCurrentLiabilities 12M 10M 10M 10M 15M 15M 10M
totalCurrentLiabilities 20M 19M 18M 16M 23M 24M 19M
longTermDebt 17M 18M 19M 20M 20M 21M 21M
deferredRevenueNonCurrent 9M 10M 12M 13M 13M 12M 13M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 43 000 43 000 43 000 43 000 42 000 24M 200 000
totalNonCurrentLiabilities 27M 28M 31M 32M 33M 33M 34M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 17M 21M 21M 22M 23M 23M 23M
totalLiabilities 47M 47M 49M 48M 56M 57M 52M
preferredStock 160M 0 0 0 0 0 0
commonStock 1000.000 1000.000 1000.000 0 0 0 0
retainedEarnings -364M -346M -330M -312M -295M -275M -253M
accumulatedOtherComprehensiveIncomeLoss 37 000 -174 000 -229 000 -235 000 -919 000 -2M -2M
othertotalStockholdersEquity 317M 475M 472M 470M 468M 465M 463M
totalStockholdersEquity 113M 128M 142M 158M 172M 188M 208M
totalEquity 113M 128M 142M 158M 172M 188M 208M
totalLiabilitiesAndStockholdersEquity 160M 175M 191M 206M 228M 246M 260M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 160M 175M 191M 206M 228M 246M 260M
totalInvestments 120M 132M 144M 156M 184M 199M 201M
totalDebt 20M 21M 21M 22M 23M 23M 23M
netDebt 9M 12M 8M 7M 13M 13M 276 000
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-21 2023-11-09 2023-08-07 2023-05-11 2023-03-29 2022-11-10 2022-08-10
acceptedDate 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -18M -16M -18M -17M -20M -22M -23M
depreciationAndAmortization 497 000 462 000 458 000 467 000 462 000 439 000 408 000
deferredIncomeTax -3M -1M -1M 0 0 0 0
stockBasedCompensation 2M 2M 2M 2M 2M 2M 2M
changeInWorkingCapital 2M -3M 518 000 -9M -774 000 5M -2M
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables 0 0 0 -7M 8M 0 -3M
otherWorkingCapital 2M -3M 518 000 -3M -9M 5M -819 000
otherNonCashItems 3M 744 000 731 000 -133 000 234 000 644 000 894 000
netCashProvidedByOperatingActivities -14M -17M -15M -23M -18M -13M -21M
investmentsInPropertyPlantAndEquipment -6000.000 -165 000 -32 000 -3000.000 -184 000 -735 000 -429 000
acquisitionsNet 0 -13M -14M 0 0 0 0
purchasesOfInvestments -32M -36M -54M -43M -25M -48M -31M
salesMaturitiesOfInvestments 48M 49M 67M 72M 42M 50M 31M
otherInvestingActivites -1.000 13M 14M 0 0 0 0
netCashUsedForInvestingActivites 16M 13M 14M 29M 16M 1M -868 000
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 106 000 0 147 000 0 144 000 0 252 000
commonStockRepurchased 0 0 141 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 106 000 0 -141 000 0 0 0 0
netCashUsedProvidedByFinancingActivities 106 000 0 147 000 0 144 000 0 252 000
effectOfForexChangesOnCash 0 0 -14M 0 0 0 0
netChangeInCash 2M -4M -1M 6M -1M -12M -21M
cashAtEndOfPeriod 11M 11M 15M 16M 11M 12M 24M
cashAtBeginningOfPeriod 9M 15M 16M 11M 12M 24M 46M
operatingCashFlow -14M -17M -15M -23M -18M -13M -21M
capitalExpenditure -6000.000 -165 000 -32 000 -3000.000 -184 000 -735 000 -429 000
freeCashFlow -14M -17M -15M -23M -18M -14M -21M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-21 20:05 ET
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
2024-02-27 12:00 ET
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
2023-12-05 12:00 ET
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
2023-11-09 21:05 ET
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-07 12:00 ET
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
2023-10-23 14:30 ET
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
2023-10-18 11:00 ET
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
2023-10-17 11:00 ET
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
2023-10-16 11:00 ET
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
2023-09-28 11:00 ET
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
2023-09-12 12:05 ET
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
2023-09-05 20:15 ET
Bolt Biotherapeutics to Participate in September Investor Conferences
2023-08-07 20:10 ET
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-03 11:30 ET
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
2023-07-31 21:27 ET
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
2023-05-30 12:00 ET
BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
2023-05-25 21:05 ET
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
2023-05-11 20:05 ET
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
2023-04-26 14:00 ET
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
2023-03-29 20:15 ET
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-03-29 20:05 ET
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
2023-03-14 20:30 ET
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
2023-02-28 13:00 ET
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
2023-02-01 13:00 ET
Bolt Biotherapeutics to Present at February Investor Conferences
2022-12-14 21:43 ET
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
2022-11-10 21:05 ET
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-11-07 13:00 ET
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
2022-11-01 12:00 ET
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
2022-08-31 11:30 ET
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-10 20:05 ET
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-05-27 12:00 ET
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
2022-05-12 20:05 ET
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
2022-04-07 12:00 ET
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
2022-03-30 20:05 ET
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
2022-03-08 21:30 ET
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
2022-02-02 13:00 ET
Bolt Biotherapeutics to Participate in Upcoming February Conferences
2022-01-06 13:00 ET
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
2021-12-16 13:00 ET
Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
2021-12-06 11:00 ET
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
2021-12-02 11:00 ET
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
2021-11-19 13:00 ET
Bolt Biotherapeutics Announces Changes to its Board of Directors
2021-11-12 12:00 ET
Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-09 09:05 ET
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
2021-11-08 13:00 ET
Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
2021-10-01 12:00 ET
Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
2021-09-08 11:30 ET
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
2021-09-02 12:00 ET
Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
2021-08-27 00:00 ET
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
2021-08-26 20:05 ET
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
2021-08-12 20:05 ET
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
2021-06-04 13:00 ET
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
2021-06-02 12:01 ET
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
2021-06-02 12:00 ET
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
2021-05-13 20:05 ET
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights
2021-04-10 12:30 ET
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
2021-04-08 11:00 ET
Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
2021-03-31 20:05 ET
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
2021-02-09 21:05 ET
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SEC forms

Show financial reports only

SEC form 10
2024-03-21 16:10 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-09 16:10 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-07 16:08 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-07 16:06 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-13 16:55 ET
Bolt Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-11 16:11 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:09 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:09 ET
Bolt Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-29 16:15 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-29 16:13 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-29 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q3
SEC form 10
2022-08-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q2
SEC form 10
2022-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q1
SEC form 10
2022-03-30 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q4
SEC form 10
2021-11-09 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q3
SEC form 8
2021-08-12 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-05-13 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q1
SEC form 8
2021-05-13 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q1